Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056178 | 0.91 | GRIN2B (0.58) | SLC6A2SLC6A4SLC6A3GRIN2BSLC18A3 | |
| SCHEMBL17284447 | 0.87 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL22878379 | 0.87 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL17282047 | 0.84 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL9392408 | 0.83 | SLC18A3 (0.66) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL15824014 | 0.81 | GRIN2B (0.59) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL8442356 | 0.81 | KDM4E (0.68) | GRIN2BAGTR2KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL12359041 | 0.80 | KDM4E (0.49) | SLC6A2SLC6A4SLC6A3PKMKDM4E | |
| SCHEMBL15823665 | 0.80 | SLC18A3 (0.62) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 | |
| SCHEMBL15823666 | 0.80 | SLC18A3 (0.62) | SLC6A2SLC6A4SLC6A3GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SLC6A2 4782/4885SLC6A4 4398/4885SLC6A3 4693/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SLC6A2 4782/4885SLC6A4 4398/4885SLC6A3 4693/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | SLC6A2 4782/4885SLC6A4 4398/4885SLC6A3 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.